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Epidemiology and current clinical challenge of 
tuberculosis 
T. Schaberg. Clzesf Clink Ihircrctedt, Deacowrss Hospital, Rotenbutg, 
Germany 
The world is currently facing a widespread tuberculosis epidemic. 
According to the World Health Organization, more than 1.8 billion 
people are infected with Mycobacterium tuberculosic worldwide. The 
current prevalence of active tuberculosis is more than 22 million, and 
each year at least 8 million new cases will occur as well as 3 million 
deaths. Therefore, between 1990 and 2000, more than 30 million 
people will die from tuberculosis-more than ever before within a 
decade. More than 90%) of all new cases and deaths occur in 
developing countries, which are struggling under the enormous 
economic burden induced by this single disease. Most cases can be 
observed in Sub-Saharan Africa and South-East Asia. In both these 
regions, infection with HIV is also endemic, resulting in a 14% 
infection rate in all TB cases. Moreover, tuberculosis is still the main 
cause of death in HIV-positive people. To make things worse, we are 
observing a growing number of resistant M .  tirbercirlosis strains 
worldwide (e.g. 6.6% single drug resistance in previously untreated 
patients and 13% multidrug resistance in patients with a history of 
previous antituberculous therapy). Therefore, the main challenges for 
the coming years are the implementation of sufficient TB-control 
programs worldwide and the battle against resistance. However, 
without strong financial support froin the developed countries, we 
will not achieve this goal. 
Mycobacterial diseases 
(s1211 Genetics of drug resistance in mycobacteria 
A. Telenti. Dioisioii of hfertioirs Diseases, Centre Hospiralier 
Unioersitaire kudois ,  Lausaizm, Switzerland 
While the global niagnitude of the muitidrug-resistant tuberculosis 
(MDR-TB) problem is not well known, gaining imight into the 
mechanisms of resistance and into the pathogenicity and trans- 
niissibility of MDK-TB will be important for future control of the 
disease. Mutations in the katC, i d i A ,  ahpC and kasA genes are found 
in 75-90% of isoniazid-resistant strains, and rifampin resistance is 
associated with rpoB inutatioris (95%). Genetic information is also 
available for pyrazinaniide (pncA, .fasi), ethambutol (embB), strepto- 
mycin (16s rDNA and rpsL), clarithromycin (23s rDNA), 
aniikacin-kananiycin (16s rDNA), and the fluoroquiiiolones (WrA, 
g y ~ B ,  &A). At a practical level, these data allow the development of 
novel resistance testing methodologies, and may permit better design 
of MDR-TB treatnient strategies. Mutation analysis may assist in the 
assessment of the pathogenicity of MDR-TB strains. In the future, 
knowledge of the molecular mechanisms of action of antituberculous 
drugs, the availability of the complete tuberculosis genome sequence, 
together with protein structural information and conibinatorial 
chemistry, may lead to new drugs. 
Vaccination strategies for tuberculosis 
S.H.E. Kauhann. Max Planck Insfitut, D e p .  of Iniiniirrolo‘qx B c r h ,  
Ccrinany 
Tuberculosis constitutes a major global health threat. Although UCG 
represents a vaccine capable of conferring protection against child- 
hood tuberculosis, it fails to provide sufficient protection against the 
most prevalent form of the disease, adult pulmonary tuberculosis. 
Thus, novel vaccination strategies against tuberculosis are urgently 
required. Tuberculosis is a chronic infectious disease caused by Myco- 
bacteriim tirberiulosis, which is capable of persisting in macrophages. 
Acquired resistance depends on multiple T-cell populations, com- 
prising not only CD4 T-cells but also CD8 T-cells and uncon- 
ventional T-cells. Activation of niycobactericidal mechanisms in 
macrophages by interferon-gainma and other cytokines from T-cells 
is crucial for controlling the pathogen. In addition, other T-cell 
functions are required for optimal protection. Thus, any future 
vaccine has to mobilize the most appropriate combination of T-cells 
needed for control of M .  tubercirlosis in the host. From an inimuno- 
logic standpoint, BCG may fail to induce the appropriate com- 
bination of T-cells and/or lack protective antigens. Vaccine strategies 
currently pursued include: secreted antigens in adjuvant; naked 
DNA; recombinant bacterial or  viral vaccine carriers expressing 
specific antigem of M. fr~bcrruiosis; M.  ruberrdosis deletion mutants; 
iiiiproved recombinant BCG capable of stimulating the appropriate 
T-cell combination and expressing unique antigens of M.  tuberculosis. 
The potential advantages and disadvantages of these different vaccine 
candidates will be discussed. 
I S123 I Progress in antimycobacterial treatment 
J.E Murray. Urtivcrsity .f Calijirrria, Sun Franrisio, CA, CJSA; 
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The five standard ‘first-line’ antimycobacterial agents used for the 
treatment and prevention of Myrobncterium tu6erculosis disease were 
developed well over a quarter ofa  century ago: streptomycin (1944), 
isoniazid (1952), pyrazinaniide (1952), ethambutol (1961), atid 
rifampicin (1966). Since then, the development of truly novel 
compounds that would significantly add to the available therapeutic 
armamentariuni has been disappointingly slow, especially in view of 
the well-publicized outbreaks of multidrug-resistant tuberculosis 
(MDR-TB) and the identification by WHOAUATLD of numerous 
‘hot-spots’, regions of the world where there is an alarmingly high 
prevalence of MDR-TB. Current new drugs of interest are the 
following. 
Fluoroquinolones. Several fluoroquinolones, which have become 
the most important ‘second-line’ antituberculosis drugs, are available, 
although thorough clinical comparisons are scarce. Because of its 
apparent safety and good activity, levofloxacin may be the agent of 
choice. Sparfloxacin is also effective against A4. tubercirlosis, but photo- 
toxicity is a problem in 10% of recipients (may be lower in dark- 
skinned persons). Because of its anti-M. ruberrrrlosis activity, moxi- 
floxacin is 3n interesting new compound. 
Macrolides. N o  macrolide antibiotics with significant in vitio 
activity against M .  tubmulosis have been identified. In contrast, 
clarithroniycin has been shown to be effective in the treatment of 
disseminated Myiobactrriuni aoium complex (MAC) disease, and both 
clarithromycin and azithroniycin have been approved in the USA for 
prophylaxis against MAC. 
Rifaniycin derivatives. Rifabutin is approved in the USA for 
prophylaxis against MAC and is used in several countries for the 
treatment of tuberculosis. It has substantial cross-resktance with 
rifampicin, but because of relatively little bidirectional drug inter- 
action with indinavir, the CDC has recoinmended that rifabntin be 
used in place of rifampicin in the treatment of HIV-infected tuber- 
culosis patients for whom an HIV protease inhibitor is indicated. 
Rifapentine is of considerable interest because of its long half-life and 
the possibility of once-weekly dosing; a phate 111 trial is now under- 
way and experimental studies suggest that the combination of rifa- 
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pentine and isoniazid. once weekly for 3 months, provides highly 
effective chenioprophylaxis. 
Other agents: Information about in i'itro and to a lesser extent irr 
tivo activities of two oxazolidinonc compounds (U-I 00592 and U- 
1 Oll7of)) and .I nitroimidaeole conipound (PA-8.24) suggest a possiblc. 
future role for one or more of these agents. 
In conclucion, development of effective new antimycobacterial 
agents has I~ggcd f.ir behind the need for thein. lnipruved public- 
priwte sector collaboration is needed to remedy the deficiency. 
Clinical implications of antibiotics resistance 
in developing countries 
151261 Use and misuse of antibiotic policies to control 
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The use ofantibiotics has led to the emergence o f a  variety ofresistant 
bacteria which have cleai-ly added to the challenge of controlling 
infections with new agents. 
Misuse of antibiotics is responsible for a general pool of resistant 
\train< in the population where there is unrestricted sale of antibiotics, 
i.e. over the counter. 
Appropriate use of antibiotic policies to control drug resistance 
should be encouraged and implemented. In order to do so, an 
.intibiotic conunittee should be responsible for tlie formulation and 
supervision of nn antibiotic pohcy.The policy will improve patient 
care hy considrred iise of antibiotics for prophylaxis and therapy, 
make hettcr use of finance, retdrd the eiiiei-gence of multiplc 
antibiotic-re\irtait bacteria and improve education of junior doctor5 
by providing guidelines for appropriate therapy. 
The antibiotic committee will have to make rational choices 
among cquiv.ilent antibiotics and classes of drugs in order to sclcct 
the least expensive. most effective 3gents.Cost should determine tlie 
telec~ion when niicrobiological, pharniacologic and other relevant 
propertics are similar. 
Data on antibiotic susceptibility of bacterial isolates from the local 
area will assist the coninlittee in producing etfective guidance for the 
patient population.The 1abor.itory should give data on  the extent of 
resistance to a particular antibiotic. When n o  local microbiology 
I h m t o r y  exicts, the ~ntibiotic policy should be based upon a baric 
formulary; when resources for i i i i c rob io lo~~  are scarce, priority 
should be given to examination of samples from nosocominl lifc- 
threatening cases. 
Inappropri'ite use o f  antibiotic policies ha5 limited the choice of 
antibiotics, and there 19 a need for iiiore prudent use ofmtibiotics in 
the treatinent ofinfections, c\pecially ui developiiig countries. 
The clinical relevance of antibiotic resistance 
for the management of pneumonia in 
developing countries 
K. P. Klugniaii. .\fRC/S.4 LtIR 111 7TS  Pwuniotorcul D i w s c s  Rcscarrli 
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There is now widejpread in vitru resistance to the coninion d r u g  
used for the management of pneumonia in developing countries. 
Data from both developed and developing countries, however, show 
that iiiore than 99% of pneuniococcl identified as penicillin resistant 
in the laboratory can be treated by adequate intravenous doses of 
penicillin or .urnpicillin. Trimethoprim-sulfaiiiethoxJzolr I \  leu active 
than mioxycillin for the nianagenient of scvcre pneumonia 
in  developing countries, The lesser activity of 
trimethoprini-sulfanietho~azole wac not directly related t o  level\  of 
antimicrobial resistance to that agent, suggectiq tli'it anioxvc.illin I \  
intrinsically more active against the coninion bacteri,il agent\ cau\ing 
pneumonia. Macrolide revstance has emerged as a major problem in  
Asia, with 8O'IB of pneuniococci isolated from children in China  
exhibiting re\istance to this class of agent. Guideline\ h r  the 
manageincnt of pneuinonia reiommLmd th'it tlie breakpoints for 
penicillin resistance should be increased, so that clinicians are not 
faced with dilemma of treating 'resistmt' strains with peiiicilhii. 
Nasopharyngeal screening programs give data on mtimicrubi.il 
resistance that are comparable to those obt'iined koni sterile-\itc 
speciniens. More data are required on the impact of penicillin 
resistance on the oral management of pnrunioni.~. (:iirrent dau  
would suggest that, where affordable, ordl amoxycillin \hould replaw 
crimethoprim-siilf~iiiethoxazole as the drug of choice fix the 
management of moderate to severe pncuniococc,~l piiciniioiiici i n  
developing countrics. 
Short course antibiotic therapy with 
macrolides 
Risk-benefit of short-course therapy with 
macrolides 
J.C. Pecht.rc. Chriversiiy C;[ ,r iwo A h f .  Srlrool, Dcyt. Gurc~ia & 
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Due to favorable plidriiiacokinetics, shorter therapeutic regimens are 
now used with some of the newer macrolides. Thcte product\ ,ire 
characterized by rapid and substmtial intraccllul'ir accumulation, 
pxticul'irly in the lysosome~, followed by slow releaw from the cell\. 
so that intracellular concentrations can wrpacr blood c~ncen t r a t~ons  
by several hundred-fold. Among nixrohde\, azithromycin display\ 
the most important intracellular accumulatioii. making possible 
umplified docing. Most m.icrolide-~iisc.eptible respiratory t r x t  
infections can be etiiciently treated by once-a-day doring for 3 day\ 
with azithroinyrin; genital and eye infections causcd by W m y d i ~ i  
iruchonzatis are controlled with a single do\? of the drug. There I\ :I 
trend to extend the concept ufa cingle therapeutic dow in respir.itory 
infections. more p.irticularly in acute utitij media 'nid pharyiigitis, 
with the scinie ton1 dose as in the more conventional t r rmiet i t  (30 
m g i k g  for a child). Compared to the 3-day regimen, the single dosc 
assures the smie  serum hdf-life and AUC, but ni~xiii ium antibiotic 
concentrcitioiis appear earlier (at day 1 versus day 3)  Jnd reach higher 
levels. In theory, this could provide improved efficacy and  11mit the 
risk of resistance selection. The  single dose could l e d  t o  1 INPo 
conipliance if the drug I\ taken in presence of hexh  perwnnel. 
Improved compliance decreases the risk oftherapcutir failure md thc 
cost. Possible inconvenience includes more ride sffectc elwicxted 
with drug concentr&nis, particularly the gastruinte\tinal manifest- 
ations. 
Overview of azithromycin therapy 
M. Ilunne. W x r  CLwtrul Rmxr-cli, Groror i ,  C7,' 1.:5..1 
Azithroniycin (AZ) has proven in vitro bacteriologic xtivity a g ~ i ~ i s t  
many important comiiiunity-'isqiilreJ Gran-po\it~ve md <;ran- 
negative pathogens, J\ well J\ the xypical respiratory pclthogen\ I n  
